NCT02008227 · OUTCOME

EORTC QLQ-LC13 Questionnaire Score: Coughing

A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy · Source last updated 2019-12-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: Units on a scale
Interval / dispersion: Standard Deviation
Time frame: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)

What was measured

QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for coughing.

Analysis population: The PP-ITT analysis set. Here, 'n' signifies those participants evaluated for this measure at specific time point for each group respectively. All 850 participants contributed to the endpoint but not all completed evaluation of every timepoint. Convention 'CxDx' refers to cycle number and day number.

Groups in this outcome

Docetaxel

Docetaxel 75 milligrams per square meter (mg/m\^2) was administered intravenously (IV) on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.

Atezolizumab

Atezolizumab 1200 mg was administered IV on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Docetaxel	425
Atezolizumab	425

Reported measurements

Coughing: Baseline (n= 383, 406)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	38.73	29.64	Not reported	Not reported	Not reported
Atezolizumab	37.27	27.23	Not reported	Not reported	Not reported

Coughing: C2D1(n= 333, 360)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	36.54	28.04	Not reported	Not reported	Not reported
Atezolizumab	37.50	28.33	Not reported	Not reported	Not reported

Coughing: C3D1(n= 250, 298)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	33.73	27.46	Not reported	Not reported	Not reported
Atezolizumab	33.89	24.99	Not reported	Not reported	Not reported

Coughing: C4D1(n= 219, 272)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	31.35	24.13	Not reported	Not reported	Not reported
Atezolizumab	32.48	25.52	Not reported	Not reported	Not reported

Coughing: C5D1(n= 164, 235)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	32.72	23.49	Not reported	Not reported	Not reported
Atezolizumab	31.35	25.52	Not reported	Not reported	Not reported

Coughing: C6D1(n= 147, 219)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	31.75	24.78	Not reported	Not reported	Not reported
Atezolizumab	31.05	24.73	Not reported	Not reported	Not reported

Coughing: C7D1(n= 87, 185)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	32.95	24.64	Not reported	Not reported	Not reported
Atezolizumab	30.99	25.07	Not reported	Not reported	Not reported

Coughing: C8D1(n= 69, 166)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	30.43	28.43	Not reported	Not reported	Not reported
Atezolizumab	29.12	25.73	Not reported	Not reported	Not reported

Coughing: C9D1(n= 50, 150)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	24.67	17.57	Not reported	Not reported	Not reported
Atezolizumab	29.11	24.52	Not reported	Not reported	Not reported

Coughing: C10D1(n= 47, 140)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	23.40	19.55	Not reported	Not reported	Not reported
Atezolizumab	27.86	22.83	Not reported	Not reported	Not reported

Coughing: C11D1(n= 37, 129)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	21.62	19.59	Not reported	Not reported	Not reported
Atezolizumab	27.39	23.37	Not reported	Not reported	Not reported

Coughing: C12D1(n= 30, 129)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	20.00	18.77	Not reported	Not reported	Not reported
Atezolizumab	25.06	23.95	Not reported	Not reported	Not reported

Coughing: C13D1(n= 19, 121)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	15.79	17.10	Not reported	Not reported	Not reported
Atezolizumab	24.79	23.78	Not reported	Not reported	Not reported

Coughing: C14D1(n= 18, 119)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	16.67	17.15	Not reported	Not reported	Not reported
Atezolizumab	24.37	22.42	Not reported	Not reported	Not reported

Coughing: C15D1(n= 16, 110)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	12.50	16.67	Not reported	Not reported	Not reported
Atezolizumab	25.76	23.31	Not reported	Not reported	Not reported

Coughing: C16D1(n= 13, 106)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	20.51	21.68	Not reported	Not reported	Not reported
Atezolizumab	24.53	22.21	Not reported	Not reported	Not reported

Coughing: C17D1(n= 11, 94)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	21.21	16.82	Not reported	Not reported	Not reported
Atezolizumab	24.82	23.92	Not reported	Not reported	Not reported

Coughing: C18D1(n= 10, 90)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	26.67	21.08	Not reported	Not reported	Not reported
Atezolizumab	26.30	24.22	Not reported	Not reported	Not reported

Coughing: C19D1(n= 9, 82)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	22.22	16.67	Not reported	Not reported	Not reported
Atezolizumab	25.61	26.86	Not reported	Not reported	Not reported

Coughing: C20D1(n= 9, 78)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	25.93	14.70	Not reported	Not reported	Not reported
Atezolizumab	28.21	26.36	Not reported	Not reported	Not reported

Coughing: C21D1(n= 9, 73)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	22.22	16.67	Not reported	Not reported	Not reported
Atezolizumab	28.77	27.95	Not reported	Not reported	Not reported

Coughing: C22D1(n= 8, 67)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	25.00	38.83	Not reported	Not reported	Not reported
Atezolizumab	22.89	23.36	Not reported	Not reported	Not reported

Coughing: C23D1(n= 8, 64)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	20.83	17.25	Not reported	Not reported	Not reported
Atezolizumab	23.44	26.35	Not reported	Not reported	Not reported

Coughing: C24D1(n= 5, 62)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	26.67	14.91	Not reported	Not reported	Not reported
Atezolizumab	24.73	23.33	Not reported	Not reported	Not reported

Coughing: C25D1(n= 3, 58)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	33.33	0.00	Not reported	Not reported	Not reported
Atezolizumab	25.86	23.40	Not reported	Not reported	Not reported

Coughing: C26D1(n= 3, 53)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	44.44	19.25	Not reported	Not reported	Not reported
Atezolizumab	26.41	24.77	Not reported	Not reported	Not reported

Coughing: C27D1(n= 3, 50)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	11.11	19.24	Not reported	Not reported	Not reported
Atezolizumab	24.67	22.14	Not reported	Not reported	Not reported

Coughing: C28D1(n= 2, 46)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	16.67	23.57	Not reported	Not reported	Not reported
Atezolizumab	20.29	20.46	Not reported	Not reported	Not reported

Coughing: C29D1(n= 2, 38)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	16.67	23.57	Not reported	Not reported	Not reported
Atezolizumab	19.30	22.77	Not reported	Not reported	Not reported

Coughing: C30D1(n= 1, 31)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	0.00	NA	Not reported	Not reported	Data not reported because SD was non-estimable since only 1 participant was evaluated for this category.
Atezolizumab	18.28	20.80	Not reported	Not reported	Not reported

Coughing: C31D1(n= 0, 24)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	NA	NA	Not reported	Not reported	Data not reported because no participant was evaluated for this category
Atezolizumab	23.61	25.02	Not reported	Not reported	Not reported

Coughing: C32D1(n= 0, 23)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	NA	NA	Not reported	Not reported	Data not reported because no participant was evaluated for this category
Atezolizumab	26.09	19.99	Not reported	Not reported	Not reported

Coughing: C33D1(n= 0,16)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	NA	NA	Not reported	Not reported	Data not reported because no participant was evaluated for this category
Atezolizumab	27.08	32.70	Not reported	Not reported	Not reported

Coughing: C34D1(n= 0, 14)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	NA	NA	Not reported	Not reported	Data not reported because no participant was evaluated for this category
Atezolizumab	26.19	29.75	Not reported	Not reported	Not reported

Coughing: C35D1(n= 0, 11)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	NA	NA	Not reported	Not reported	Data not reported because no participant was evaluated for this category
Atezolizumab	21.21	22.47	Not reported	Not reported	Not reported

Coughing: C36D1(n= 0, 8)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	NA	NA	Not reported	Not reported	Data not reported because no participant was evaluated for this category
Atezolizumab	25.00	15.43	Not reported	Not reported	Not reported

Coughing: C37D1(n= 0, 5)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	NA	NA	Not reported	Not reported	Data not reported because no participant was evaluated for this category
Atezolizumab	26.67	14.91	Not reported	Not reported	Not reported

Coughing: C38D1(n= 0, 2)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	NA	NA	Not reported	Not reported	Data not reported because no participant was evaluated for this category
Atezolizumab	33.33	0.00	Not reported	Not reported	Not reported

Coughing: EOT(n= 262, 246)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	35.75	27.03	Not reported	Not reported	Not reported
Atezolizumab	38.48	26.95	Not reported	Not reported	Not reported

Coughing: Pro Week 6 Pd(n= 0,1)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	NA	NA	Not reported	Not reported	Data not reported because no participant was evaluated for this category
Atezolizumab	33.33	NA	Not reported	Not reported	Data not reported because SD was non-estimable since only 1 participant was evaluated for this category.

Coughing: Survival FU 1 (n= 2, 1)

Values in Units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	50.00	23.57	Not reported	Not reported	Not reported
Atezolizumab	33.33	NA	Not reported	Not reported	Data not reported because SD was non-estimable since only 1 participant was evaluated for this category.

Complete source fields

classes

categories
measurements
group Id
OG000
spread
29.64
value
38.73
group Id
OG001
spread
27.23
value
37.27
title
Coughing: Baseline (n= 383, 406)
categories
measurements
group Id
OG000
spread
28.04
value
36.54
group Id
OG001
spread
28.33
value
37.50
title
Coughing: C2D1(n= 333, 360)
categories
measurements
group Id
OG000
spread
27.46
value
33.73
group Id
OG001
spread
24.99
value
33.89
title
Coughing: C3D1(n= 250, 298)
categories
measurements
group Id
OG000
spread
24.13
value
31.35
group Id
OG001
spread
25.52
value
32.48
title
Coughing: C4D1(n= 219, 272)
categories
measurements
group Id
OG000
spread
23.49
value
32.72
group Id
OG001
spread
25.52
value
31.35
title
Coughing: C5D1(n= 164, 235)
categories
measurements
group Id
OG000
spread
24.78
value
31.75
group Id
OG001
spread
24.73
value
31.05
title
Coughing: C6D1(n= 147, 219)
categories
measurements
group Id
OG000
spread
24.64
value
32.95
group Id
OG001
spread
25.07
value
30.99
title
Coughing: C7D1(n= 87, 185)
categories
measurements
group Id
OG000
spread
28.43
value
30.43
group Id
OG001
spread
25.73
value
29.12
title
Coughing: C8D1(n= 69, 166)
categories
measurements
group Id
OG000
spread
17.57
value
24.67
group Id
OG001
spread
24.52
value
29.11
title
Coughing: C9D1(n= 50, 150)
categories
measurements
group Id
OG000
spread
19.55
value
23.40
group Id
OG001
spread
22.83
value
27.86
title
Coughing: C10D1(n= 47, 140)
categories
measurements
group Id
OG000
spread
19.59
value
21.62
group Id
OG001
spread
23.37
value
27.39
title
Coughing: C11D1(n= 37, 129)
categories
measurements
group Id
OG000
spread
18.77
value
20.00
group Id
OG001
spread
23.95
value
25.06
title
Coughing: C12D1(n= 30, 129)

denoms

counts
group Id
OG000
value
425
group Id
OG001
value
425
units
Participants

description

dispersion Type

Standard Deviation

groups

description
Docetaxel 75 milligrams per square meter (mg/m\^2) was administered intravenously (IV) on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.
id
OG000
title
Docetaxel
description
Atezolizumab 1200 mg was administered IV on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.
id
OG001
title
Atezolizumab

param Type

MEAN

population Description

The PP-ITT analysis set. Here, 'n' signifies those participants evaluated for this measure at specific time point for each group respectively. All 850 participants contributed to the endpoint but not all completed evaluation of every timepoint. Convention 'CxDx' refers to cycle number and day number.

reporting Status

POSTED

time Frame

Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)

title

EORTC QLQ-LC13 Questionnaire Score: Coughing

type

SECONDARY

unit Of Measure

Units on a scale

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice